Riddell, Stanley R.

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,112

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery

CAR-T cell therapy researchBarrier Structure and Function Studies

Cited by 1,400

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,156

Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells

Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood

T-cell and B-cell ImmunologyMonoclonal and Polyclonal Antibodies Research

Cited by 1,122

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,016

De novo design of potent and selective mimics of IL-2 and IL-15

Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida, C., Ali, L. R., Quijano-Rubio, A., Ruterbusch, M., Leung, I., et al. (2019) · Nature

Protein Structure and DynamicsChemical Synthesis and Analysis

Cited by 531

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Hirayama, A. V., Gauthier, J., Hay, K. A., Voutsinas, J. M., Wu, Q., Gooley, T., Li, D., Cherian, S., Chen, X., Pender, B. S., et al. (2019) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 355

Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting

Srivastava, S., Salter, A. I., Liggitt, D., Yechan-Gunja, S., Sarvothama, M., Cooper, K., Smythe, K. S., Dudakov, J. A., Pierce, R. H., Rader, C., et al. (2019) · Cancer Cell

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 334

Serial Transfer of Single-Cell-Derived Immunocompetence Reveals Stemness of CD8+ Central Memory T Cells

Graef, P., Buchholz, V. R., Stemberger, C., Flossdorf, M., Henkel, L., Schiemann, M., Drexler, I., Höfer, T., Riddell, S. R., & Busch, D. H. (2014) · Immunity

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 311

The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood

CAR-T cell therapy researchChronic Lymphocytic Leukemia Research

Cited by 266

HLA engineering of human pluripotent stem cells

Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy

Pluripotent Stem Cells ResearchCRISPR and Genetic Engineering

Cited by 253

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Gauthier, J., Bezerra, E. D., Hirayama, A. V., Fiorenza, S., Sheih, A., Chou, C. K., Kimble, E. L., Pender, B. S., Hawkins, R. M., Vakil, A., et al. (2021) · Blood

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 205

Characterization of Human CD8+ T Cells Reactive with Mycobacterium tuberculosis–infected Antigen-presenting Cells

Lewinsohn, D. M., Alderson, M. R., Briden, A. L., Riddell, S. R., Reed, S. G., & Grabstein, K. H. (1998) · The Journal of Experimental Medicine

Tuberculosis Research and EpidemiologyImmunotherapy and Immune Responses

Cited by 165

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver Mutations

Veatch, J. R., Jesernig, B. L., Kargl, J., Fitzgibbon, M., Lee, S. M., Baik, C., Martins, R., Houghton, A. M., & Riddell, S. R. (2019) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 89

Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial

Seo, Y. D., Lu, H., Black, G., Smythe, K., Yu, Y., Hsu, C., Ng, J., Hermida de Viveiros, P., Warren, E. H., Schroeder, B. A., et al. (2023) · JAMA Oncology

Sarcoma Diagnosis and TreatmentImmunotherapy and Immune Responses

Cited by 31